We joined Jean Bourhis at ESMO 2019 to learn a little more about the oral antagonist of inhibitor of apoptosis proteins (IAPs), Debio 1143, which is thought to act as a chemo-radio-sensitizer to enhance treatment efficacy.
1. Please outline the current burden of head and neck cancer? (00:06)
2. Debio 1143 is currently under investigation for head and neck cancer, amongst several other cancers – please describe how this compound works? (00:44)
3. A Phase II trial of Debio 1143 in patients with head and neck cancer recently concluded, what were the key results and what is their potential impact? (01:21)
4. What are the next steps in the development of Debio 1143 for head and neck cancer? (01:55)
Jean Bourhis has participated in advisory boards for Merck, MSD, BMS and AstraZeneca.
Filmed at the European Society for Medical Oncology (ESMO) Congress 2019, Barcelona, Spain.
touchONCOLOGY.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
Share this Video
Related Videos In Head and Neck Cancer
Jean Bourhis, ESMO 2019 – Debio 1143 in head and neck cancer
We joined Jean Bourhis at ESMO 2019 to learn a little more about the oral antagonist of inhibitor of apoptosis proteins (IAPs), Debio 1143, which is thought to act as a chemo-radio-sensitizer to enhance treatment efficacy. Questions 1. Please outline the current burden of head and neck cancer? (00:06) 2. Debio 1143 is currently under […]
Mike Gibson, ASCO 2019 – KEYNOTE-062 and KEYNOTE-48 trial data
Editorial Board member, Mike Gibson, reviews data presented at the ASCO 2019 annual meeting around the immune checkpoint inhibitor, pembrolizumab, in the treatment of head and neck cancers. This includes a discussion around KEYNOTE-062 (NCT02494583) and KEYNOTE-48 (NCT02358031) data, the factors that influence the choice of pembrolizumab monotherapy vs pembrolizumab plus chemotherapy and the role […]
Yungan Tao, ESMO 2018 – Developments in the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinomas
In this interview at ESMO 2018, Dr Yungan Tao speaks about the GORTEC 2004-01 randomised phase III trial which looked at 70 Gy/35 F with conventional radiotherapy versus 75 Gy/35 F with intensity-modulated radiotherapy. Dr Tao explains the results and limitations of the study and how this information adds to the body of evidence to […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!